Arvinas (ARVN) Interest & Investment Income (2017 - 2026)
Arvinas (ARVN) posted quarterly Interest & Investment Income of $6.4 million for Q1 2026, down 45.3% year-over-year from $11.7 million in Q1 2025, and down 13.51% quarter-over-quarter from $7.4 million in Q4 2025.
Arvinas (ARVN) Interest & Investment Income (2017 - 2026) Analysis & Trends
Arvinas' Interest & Investment Income history runs 10 years deep, the most recent figure standing at $6.4 million for Q1 2026.
- In Q1 2026, Interest & Investment Income fell 45.3% year-over-year to $6.4 million; the TTM figure through Mar 2026 stood at $33.1 million (down 36.95% YoY), while the FY2025 annual figure was $38.4 million, down 29.93% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $6.4 million, down from $7.4 million in the prior quarter.
- The five-year high for Interest & Investment Income was $14.3 million in Q3 2024, with the low at $1.2 million in Q1 2022.
- The 5-year median for Interest & Investment Income is $9.0 million (2023), against an average of $8.9 million.
- The sharpest annual moves came in 2022 and 2026: Interest & Investment Income surged 822.55% in 2022, then slumped 45.3% in 2026.
- Arvinas' Interest & Investment Income stood at $5.7 million in 2022, then surged by 114.04% to $12.2 million in 2023, then climbed by 5.74% to $12.9 million in 2024, then plunged by 42.64% to $7.4 million in 2025, then retreated by 13.51% to $6.4 million in 2026.
- Business Quant data shows ARVN's Interest & Investment Income at $6.4 million in Q1 2026, $7.4 million in Q4 2025, and $9.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 48.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 35.58 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 27.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 5.13 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 28.14 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Arvinas | 585.74 Mn | 17.84 Mn | - | 5.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.50 Mn |
| Mar 31, 2026 | 6.40 Mn |
| Dec 31, 2025 | 7.40 Mn |
| Sep 30, 2025 | 9.00 Mn |
| Jun 30, 2025 | 10.30 Mn |
| Mar 31, 2025 | 11.70 Mn |
| Dec 31, 2024 | 12.90 Mn |
| Sep 30, 2024 | 14.30 Mn |
| Jun 30, 2024 | 13.60 Mn |
| Mar 31, 2024 | 14.00 Mn |
| Dec 31, 2023 | 12.20 Mn |
| Sep 30, 2023 | 10.00 Mn |
| Jun 30, 2023 | 9.00 Mn |
| Mar 31, 2023 | 7.60 Mn |
| Dec 31, 2022 | 5.70 Mn |
| Sep 30, 2022 | 3.40 Mn |
| Jun 30, 2022 | 1.80 Mn |
| Mar 31, 2022 | 1.20 Mn |
| Dec 31, 2021 | 620,912.00 |
| Sep 30, 2021 | 368,545.00 |